EAST HANOVER, N.J., May 5, 2014 /PRNewswire/ -- Novartis today presented results from a pivotal Phase III trial of investigational therapy Signifor ® LAR (pasireotide LAR; SOM230) in patients with ...

This prospective, cross-sectional, and comparative study included 30 patients with acromegaly (study group) and 30 healthy subjects (control group). The subfoveal choroidal thickness (SFCT), foveal ...

In this blog post, I present three cases involving patients suspected of having possible acromegaly and discuss follow up. After reading, please share your thoughts. Case #1 is a 51-year-old man who ...

Clinicians who treat patients with acromegaly commonly show a lack of awareness of the severity and pattern of patient symptoms that can occur even when treatment suggests the condition is under ...

October 13, 2010 (Liege, Belgium) — In patients with treatment-resistant, active acromegaly, normalizing insulin-like growth factor 1 (IGF-1) levels leads to a marked reduction in cardiovascular risk, ...

Acromegaly is an endocrine disorder caused by elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels[1] Signifor LAR (pasireotide) represents a potential new option for ...

Please provide your email address to receive an email when new articles are posted on . One-third of acromegaly and growth hormone deficiency studies report discrepancies between patient-reported ...

What tests confirm a diagnosis of acromegaly? If your doctor thinks you may have acromegaly, you will be referred to a specialist, such as an endocrinologist. The specialist will give you a sugary ...

MONTREAL, Sept. 27, 2018 /CNW Telbec/ - A rare condition gets the chance to shine tonight through the power of collective art, as patient stories celebrate struggles and successes with acromegaly. At ...

Acromegaly, an endocrine disorder resulting from elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels, is associated with high mortality[1,2] Phase III data show patients on ...